Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant and ondansetron alone or in combination for prevention of postoperative nausea and vomiting after thyroid cancer surgery
ChiCTR2400089337Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of aprepitant and ondansetron in postoperative nausea and vomiting (PONV) (3 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Complete response rate within 24 hours after surgery. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
aprepitantondansetron
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on ChiCTR2400089337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089337.